Asymmetric dimethylarginine (ADMA) induces chronic kidney disease through a mechanism involving collagen and TGF-β1 synthesis.

@article{Mihout2011AsymmetricD,
  title={Asymmetric dimethylarginine (ADMA) induces chronic kidney disease through a mechanism involving collagen and TGF-β1 synthesis.},
  author={Fabrice Mihout and Nasim Shweke and Na{\"i}ke Big{\'e} and Chantal Jouanneau and Jean-Claude Dussaule and Pierre Ronco and Christos Chatziantoniou and J F Boffa},
  journal={The Journal of pathology},
  year={2011},
  volume={223 1},
  pages={37-45}
}
Asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase (NOS) inhibitor, is accumulated in plasma during chronic kidney disease (CKD). It is considered an independent mortality and cardiovascular risk factor in CKD patients. To test the involvement of ADMA in CKD progression, we investigated the effects of chronic ADMA administration on renal structure and compared these effects with NG-nitro-L-arginine methyl ester (L-NAME) treatment, a widely used exogenous inhibitor of NOS… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 36 extracted citations

Similar Papers

Loading similar papers…